search
Back to results

Ambulatory SNP Under Local Anaesthesia in a Subgroup of Breast Cancer Patients - Trial (AMBULANT)

Primary Purpose

Breast Neoplasms

Status
Unknown status
Phase
Not Applicable
Locations
Netherlands
Study Type
Interventional
Intervention
Sentinel Node Procedure under Local Anaesthesia
Sentinel Node Procedure under General Anaesthesia
Sponsored by
Medical Center Alkmaar
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Breast Neoplasms focused on measuring Sentinel Lymph Node Biopsy, Local Anaesthesia

Eligibility Criteria

18 Years - 60 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Female
  • Age 18-60 years
  • Diagnosis of invasive BC (established with core needle biopsy of the breast lesion)
  • Breast carcinoma measures > 20 mm ultrasonographically
  • Pre-operative US+FNAC is negative or inconclusive
  • No evidence of distant metastases
  • ASA Classification I-III
  • Signed informed consent

Exclusion Criteria:

  • History of previous breast surgery in the affected breast
  • History of previous axillary surgery in the ipsilateral axilla
  • History of radiation therapy (ipsilateral breast or axilla)
  • History of neo-adjuvant therapy (for the BC)
  • Known allergy to lidocain

Sites / Locations

  • Medical Center Alkmaar

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Other

Arm Label

SNPGA

SNPLA

Arm Description

Sentinel Node Procedure under General Anaesthesia

Sentinel Node Procedure under Local Anaesthesia

Outcomes

Primary Outcome Measures

Number of operations under general anaesthesia
Number of operations under local anaesthesia
The number of patients in whom breast surgery is performed ≤21 days.

Secondary Outcome Measures

Quality of Life
Quality of Life is measured with the WHOQOL-bref questionnaire
Depressive symptoms
Depressive symptoms are measured with the Centre for Epidemiological Studies-Depression scale (CES-D)
Anxiety
Anxiety is measured with the State-and-Trait-Anxiety-Inventory (STAI)

Full Information

First Posted
July 9, 2014
Last Updated
July 10, 2014
Sponsor
Medical Center Alkmaar
search

1. Study Identification

Unique Protocol Identification Number
NCT02187718
Brief Title
Ambulatory SNP Under Local Anaesthesia in a Subgroup of Breast Cancer Patients - Trial
Acronym
AMBULANT
Official Title
A Prospective Single-centre Randomised Controlled Clinical Trial Comparing Sentinel Node Procedure Under Local Anaesthesia to Traditional Sentinel Node Procedure Under General Anaesthesia in Patients <60 Years With a Breast Carcinoma >20 mm.
Study Type
Interventional

2. Study Status

Record Verification Date
July 2014
Overall Recruitment Status
Unknown status
Study Start Date
January 2015 (undefined)
Primary Completion Date
December 2016 (Anticipated)
Study Completion Date
August 2017 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Medical Center Alkmaar

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Rationale: In breast cancer (BC) patients, lymph node status is a key prognostic indicator. At present, axillary ultrasound (US) with subsequent fine needle aspiration cytology (FNAC) of suspicious lymph nodes (US+FNAC) is widely used as a pre-operative staging method. When US+FNAC is negative, a sentinel node procedure (SNP) is performed during breast surgery. Nowadays, an axillary lymph node dissection (ALND) is generally performed if one of the abovementioned diagnostic entities reveals lymph node metastases. However, the extensive role of ALND in BC patients with lymph node metastases may change or diminish in upcoming years due to emerging evidence that completion ALND (cALND) does not affect disease-free survival and overall survival in early BC patients with (sentinel) node-positive disease. Whether ALND is needed in these patients, should be based on (axillary) tumour load. Because of the fact that tumour load can only be reliably evaluated by SNP and not by US+FNAC, the role of SNP might become even more important in upcoming years. Ideally, the status of this sentinel lymph node is known prior to breast surgery, so a patient tailored treatment plan can be made and discussed with the patient before breast surgery. In this context, it would be very logical to perform a SNP under local anaesthesia (LA), prior to breast surgery. This might not only lead to significantly less two-step surgical procedures under general anaesthesia (GA), but might also lead to a reduction of depressive symptoms and anxiety and improved quality of life (QoL) of BC patients, because BC patients are in particular risk for psychological distress in the first three months after diagnosis of BC. Knowing lymph node status and the complete treatment plan as soon as possible (by performing a SNP under LA), might reduce this psychological distress. To investigate which BC patients would benefit most from SNP under LA, the investigators recently analysed 1132 BC patients retrospectively. Both prevalence of axillary lymph node metastases and prevalence of false negative results of US+FNAC were directly associated with age <60 years and with primary breast tumour size >20 mm. Hence, these BC patients might benefit most from SNP under LA. In the present study, the value of SNP under LA in these BC patients (i.e. <60 years with a breast carcinoma >20 mm) will be analysed. Objectives: Reduction of the mean number of operations under general anaesthesia per patient. Improvement of QoL. Reduction of depressive symptoms and experienced anxiety. Study design: Prospective single centre randomised controlled clinical trial. Study population: Women aged 18 to 60 years who are diagnosed with BC AND with a tumour size of >20 mm ultrasonographically AND with a negative or inconclusive pre-operative US+FNAC. Intervention: Sentinel Node Procedure under Local Anaesthesia (SNP under LA) Control: Traditional Sentinel Node Procedure under General Anaesthesia (SNP under GA) Main study parameters: Primary outcome parameters are the number of operations under GA per patient and the number of operations under LA per patient. Secondary outcome parameters are QoL, experienced depressive symptoms and anxiety. Timeline and statistics: The inclusion period will be conducted from the 1st of July 2014 to the 1st of August 2015, and 80 patients will be enrolled in this study (alpha 0.05; power 0.8). Inclusion of 80 patients will be sufficient to reduce the number of two-stage surgical procedures under general anaesthesia with 30%. Data will be analysed using descriptive statistics, Chi-squared test, Fisher's exact test, Mann-Whitney U test, Kruskall-Wallis test, students t-test, ANOVA, paired t-test, Wilcoxon signed-rank test, Friedman test, Pearson's and Spearman's rank correlation coefficients and finally logistic and linear regression analysis.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Breast Neoplasms
Keywords
Sentinel Lymph Node Biopsy, Local Anaesthesia

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
80 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
SNPGA
Arm Type
Other
Arm Description
Sentinel Node Procedure under General Anaesthesia
Arm Title
SNPLA
Arm Type
Other
Arm Description
Sentinel Node Procedure under Local Anaesthesia
Intervention Type
Procedure
Intervention Name(s)
Sentinel Node Procedure under Local Anaesthesia
Intervention Type
Procedure
Intervention Name(s)
Sentinel Node Procedure under General Anaesthesia
Primary Outcome Measure Information:
Title
Number of operations under general anaesthesia
Time Frame
6 months
Title
Number of operations under local anaesthesia
Time Frame
6 months
Title
The number of patients in whom breast surgery is performed ≤21 days.
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Quality of Life
Description
Quality of Life is measured with the WHOQOL-bref questionnaire
Time Frame
6 months
Title
Depressive symptoms
Description
Depressive symptoms are measured with the Centre for Epidemiological Studies-Depression scale (CES-D)
Time Frame
6 months
Title
Anxiety
Description
Anxiety is measured with the State-and-Trait-Anxiety-Inventory (STAI)
Time Frame
6 months
Other Pre-specified Outcome Measures:
Title
Pain during SNP under local anaesthesia
Description
Pain during SNP under local anaesthesia is measured with a Numeric Pain Rating Scale
Time Frame
6 months
Title
Duration of SNP under local anaesthesia
Time Frame
6 months
Title
Duration of SNP under general anaesthesia
Time Frame
6 months
Title
Number of lymph nodes excised by SNP under local anaesthesia
Time Frame
6 months
Title
Number of lymph nodes excised by SNP under general anaesthesia
Time Frame
6 months

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Female Age 18-60 years Diagnosis of invasive BC (established with core needle biopsy of the breast lesion) Breast carcinoma measures > 20 mm ultrasonographically Pre-operative US+FNAC is negative or inconclusive No evidence of distant metastases ASA Classification I-III Signed informed consent Exclusion Criteria: History of previous breast surgery in the affected breast History of previous axillary surgery in the ipsilateral axilla History of radiation therapy (ipsilateral breast or axilla) History of neo-adjuvant therapy (for the BC) Known allergy to lidocain
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Martijn Leenders, MD
Phone
+31624271275
Email
m.w.h.leenders@mca.nl
First Name & Middle Initial & Last Name or Official Title & Degree
Hermien Schreurs, MD, PhD
Phone
+31725484444
Email
w.h.schreurs@mca.nl
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Hermien Schreurs, MD, PhD
Organizational Affiliation
Medical Center Alkmaar
Official's Role
Principal Investigator
Facility Information:
Facility Name
Medical Center Alkmaar
City
Alkmaar
State/Province
Noord-Holland
Country
Netherlands
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Martijn Leenders, MD
First Name & Middle Initial & Last Name & Degree
Hermien Schreurs, MD, PhD
First Name & Middle Initial & Last Name & Degree
Anne Roukema, MD, PhD, Prof
First Name & Middle Initial & Last Name & Degree
Shirley Go, MD
First Name & Middle Initial & Last Name & Degree
Henk-Jan Slooten van, MD, PhD
First Name & Middle Initial & Last Name & Degree
Metha Klaver, PhD
First Name & Middle Initial & Last Name & Degree
Tjeerd Ploeg, van der, PhD

12. IPD Sharing Statement

Learn more about this trial

Ambulatory SNP Under Local Anaesthesia in a Subgroup of Breast Cancer Patients - Trial

We'll reach out to this number within 24 hrs